Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WRN | Q14191 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 5/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30862692 | 1.00 | WRN (0.44) | WRNMAPTP2RY14NPC1NR3C1 | |
| SCHEMBL30862836 | 0.92 | WRN (0.46) | WRNMAPTNR3C1MTORPIK3CA | |
| SCHEMBL27386392 | 0.92 | WRN (0.46) | WRNMAPTNR3C1MTORPIK3CA | |
| SCHEMBL30862712 | 0.91 | WRN (0.48) | WRNMAPTP2RY14NPC1RAB9A | |
| SCHEMBL30862744 | 0.91 | WRN (0.48) | WRNMAPTP2RY14NPC1RAB9A | |
| SCHEMBL30862847 | 0.88 | WRN (0.41) | WRNMAPTP2RY14MTORPIK3CA | |
| SCHEMBL30862713 | 0.88 | WRN (0.41) | WRNMAPTP2RY14MTORPIK3CA | |
| SCHEMBL30862683 | 0.88 | WRN (0.41) | WRNMAPTP2RY14MTORPIK3CA | |
| SCHEMBL30862827 | 0.86 | WRN (0.37) | WRNMTORPIK3CAPIK3CGATR | |
| SCHEMBL30862765 | 0.85 | WRN (0.40) | WRNMAPTALDH1A1DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601746-A1 | TRICYCLIC COMPOUNDS AND THEIR USES | Novartis AG (CH) | 2025-08-20 | — | — | EP | disclosed |
| CN-120077048-A | Tricyclic compounds and uses thereof | 诺华股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20240245694-A1 | Tricyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2024-07-25 | — | — | US | disclosed |
| WO-2024079623-A1 | TRICYCLIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2024-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245694-A1 | Tricyclic Compounds and their Uses | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R | WRN 2992/4885MAPT 1793/4885P2RY14 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.